J&J Close to Settling Off-Label Probes

Johnson & Johnson and the Justice Department are close to settling a protracted investigation into the company’s promotion of the antipsychotic Risperdal, for what would be one of the highest sums to date in a drug-marketing case, said people familiar with the matter.
The Wall Street Journal